TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10651663
Drug: LA-2 W
Normalized name: Aminobenzoic Acid/Ascorbic Acid/Beta Carotene/Bioflavonoid/Biotin/Boron/Calcium/Calcium Pantothenate/Choline/Chromium/Copper/Cyanocobalamin/Folic Acid/Hesperidin/Inositol/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacin/Phytonadione/Potassium/Pyridoxine/Riboflavin/Rutin/Selenium/Silicon/Thiamine/Vanadium/Vitamin A/Vitamin D/Vitamin E/Zinc 8 MG-100 MG-5000 IU-10 MG-0.3 MG-1 MG-100 MG-25 MG-10 MG-0.2 MG-2 MG-0.025 MG-0.4 MG-10 MG-10 MG-0.1 MG-20 MG-100 MG-6 MG-0.1 MG-25 MG-0.07 MG-25 MG-25 MG-15 MG-10 MG-0.025 MG-2.4 MG-15 MG-0.025 MG-5000 IU-400 IU-30 IU-30 MG Oral Tablet [TOTAL FORMULA-2 W/IRON]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-2 W (lansoprazole 30 mg b.d., amoxycillin 1 g b.d. and placebo for 2 weeks)
Study: 6384452
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg/day intravenously for three doses)
Study: 31832291
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily orally
Study: 24595923
Drug: Bevacizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (100 mg, intranasal submucosal injection, 10 mL)
Study: 17223475
Drug: Pulses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulses of vincristine (1.5 mg/m2 weekly for 2 weeks) and dexamethasone (6 mg/m2 daily for 7 days) every 10 weeks for six cycles
Study: 17223475
Drug: Conventional mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional mercaptopurine and methotrexate chemotherapy only
Study: 11583749
Drug: peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2b 1.5 microg/kg each week plus 800 mg/day ribavirin
Study: 11557910
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg)
Study: 26273747
Drug: Levobupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine plus dexmedetomidine (20 μg)
Study: 17332177
Drug: Measles-mumps-rubella vaccine
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella vaccine
Study: 17332177
Drug: Mumps vaccine
Normalized name: Mumps vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mumps vaccine
Study: 17332177
Drug: Rubella vaccine
Normalized name: Rubella vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubella vaccine
Study: 11498212
Drug: Cilomilast 15
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast 15 mg twice daily
Study: 11498212
Drug: Cilomilast 5
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast 5 mg and 10 mg
Study: 27500370
Drug: Aqueous solutions
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solutions of surfactants (anionic, non-ionic, amphoteric)
Study: 25930115
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine ointment (PIO) applied starting on post-vaccination day 7
Study: 25930115
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine ointment (PIO)
Study: 25930115
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine ointment (PIO) and control group
Study: 23220343
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention program (3-month duration including 8 weeks of exercise training, health education, home hazards evaluation/modification, medication review, and specialty consults)
Study: 21241789
Drug: Controlled-release microparticles
Normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release microparticles F-3 (TmH:EC ratio 1:2)
Study: 21241789
Drug: Controlled-release microparticles
Normalized name: Microparticulate beta-(1,3)(1,6) glucan from saccharomyces cerevisiae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release microparticles F-4 (TmH:EC ratio 1:3)
Study: 21241789
Drug: Immediate-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation (control)
Study: 12970142
Drug: Protein and
Normalized name: Protein and/or protein derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein and energy dense supplement enriched with n‐3 fatty acids and antioxidants (E)
Study: 12970142
Drug: Isocaloric isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric isonitrogenous control supplement (C)
Study: 9515594
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (i.v.IG) 1 g/kg body weight
Study: 9515594
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous human serum albumin)
Study: 9515594
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (i.v.IG)
Study: 8036475
Drug: loracarbef (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: loracarbef (200 mg b.i.d. for 7 days)
Study: 8036475
Drug: amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin (500 mg t.i.d. for 7 days)
Study: 31154414
Drug: TCZ mono
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ mono (Tocilizumab monotherapy)
Study: 26666374
Drug: Light-emitting diode
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-emitting diode therapy (LEDT) administered with a multidiode cluster probe (50 GaAIA LEDs, 850 ηm, 75 mW each diode, and 3 J per point) before exercise sessions.
Study: 23257316
Drug: Intralesion injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesion injections of pingyangmycin in combination with triamcinolone acetonide
Study: 23257316
Drug: Intralesion injections
Normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesion injections of pingyangmycin alone
Study: 21989212
Drug: Minimal acupuncture
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal acupuncture for two seconds in LI4, administered during six visits to the clinic, twice weekly.
Study: 12701865
Drug: 5 IU/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU/cc of low molecular weight heparin (LMWH) in vitrectomy infusion fluid
Study: 12701865
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin in the infusion fluid (control group)
Study: 9229416
Drug: Palliative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatments
Study: 3292159
Drug: 3 percent
Normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 percent topical minoxidil solution applied twice daily for one year to half the scalp
Study: 25617224
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (400,000 IU)
Study: 23782178
Drug: Clopidogrel (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (0.2 mg/kg/day)
Study: 21416132
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy with streptokinase (SK)
Study: 18493312
Drug: gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: gatifloxacin (10 mg/kg/day)
Study: 18493312
Drug: azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin (20 mg/kg/day)
Study: 16790698
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (≤2 mg/kg/day)
Study: 9361375
Drug: L-Arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine infusion
Study: 9361375
Drug: Oral L-Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-Arginine supplementation
Study: 1558413
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous cimetidine (300 mg every 6 hours)
Study: 17906160
Drug: Single 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200 mg dose of pirfenidone
Study: 17906160
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 mg dose of pirfenidone
Study: 17906160
Drug: Single 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 600 mg dose of pirfenidone
Study: 17906160
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 400 mg pirfenidone administered 3 times daily (tid)
Study: 16044340
Drug: Capecitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,250 mg/m2 twice daily for 14 days, followed by a 7-day rest period, n=10)
Study: 16044340
Drug: 5‐FU/LV (Mayo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/LV (Mayo Clinic regimen: LV 20 mg/m2 followed by 5‐FU 425 mg/m2, administered as an i.v. bolus on days 1‐5 every 28 days, n=10)
Study: 12402370
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program focused on coping with residual and relapse warning signs, managing drug side effects, medication compliance, and daily routines; included self-efficacy method, manuals, videotapes, small group discussions, and telephone coaching
Study: 7781143
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg i.v. before paclitaxel
Study: 7781143
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg i.v. before paclitaxel
Study: 7273650
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy (stratified for Stage III)
Study: 29294507
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen (IVA)
Study: 26062183
Drug: Three-spasm-needle therapy
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-spasm-needle therapy applied to Jiejian, Xuehaishang and Houxuehai, given once every two days for 20 days, with 3 sessions total.
Study: 26062183
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapies (Bobath therapy and lower extremities therapy) and scalp acupuncture (seven‐intelligent needles) in the control group, given once every day for 20 days, with 3 sessions total.
Study: 21214919
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire based on Azjen's Theory of Planned Behaviour
Study: 11696050
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer with low output of 0.87 mL/min
Study: 11696050
Drug: Ultrasonic nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic nebulizer with high output of 1.90 mL/min
Study: 2897516
Drug: Standard anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulant control with rabbit brain thromboplastin (therapeutic range 18‐24 s; INR 2.5‐40)
Study: 29467523
Drug: Low-dose hydrocortisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days)
Study: 23552131
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) + Optimal Medical Therapy (OMT)
Study: 9103747
Drug: 12-session cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-session cognitive-behavioral treatment (CBT12)
Study: 9103747
Drug: 4-session computer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-session computer-assisted cognitive-behavioral treatment (CBT4-CA)
Study: 8460755
Drug: Propofol and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol and fentanyl combination
Study: 27698600
Drug: Sublingual Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual Misoprostol (400 µg)
Study: 27698600
Drug: Vaginal Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal Misoprostol (400 µg)
Study: 25127240
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. rhamnosus GR‐1 and L. reuteri RC‐14 (2.5×10^9 CFU each)
Study: 25127240
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. rhamnosus GR‐1 and L. reuteri RC‐14
Study: 15841891
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and an educational pamphlet about the risks of glucocorticoid-induced osteoporosis, monitoring of drug therapy by pharmacists.
Study: 12459688
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phenylephrine 50 microg/ml and ephedrine 1.5 mg/ml
Study: 7661160
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g t.i.d.
Study: 7661160
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 0.5 g t.i.d.
Study: 7661160
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g suspension t.i.d. (re-treatment)
Study: 7661160
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 3 g (side effects)
Study: 7661160
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1.5 g (side effects)
Study: 7064879
Drug: Folic acid,
Normalized name: folic acid, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid, 10 mg daily for 3 months
Study: 7064879
Drug: Placebo (ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ascorbic acid, 10 mg daily for 3 months)
Study: 31836300
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection (ICI) alone
Study: 26934941
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of remifentanil infusion
Study: 26934941
Drug: Abrupt withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt withdrawal of remifentanil infusion
Study: 24611922
Drug: Interviewer-administered method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered method
Study: 24611922
Drug: Self-administered method
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered method
Study: 17553467
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (titrated from 37.5 mg to a maximum of 225 mg over 16 weeks)
Study: 15037872
Drug: Candesartan 8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8-16 mg daily
Study: 55715
Drug: Oral disodium
Normalized name: etidronate disodium Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disodium cromoglycate (2 g/day)
Study: 30064262
Drug: Daily quadriceps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily quadriceps exercise at home for 30 minutes (control group)
Study: 25805451
Drug: Dose delays
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose delays and reductions
Study: 21375445
Drug: Psychological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapies (relaxation training, biofeedback, multimodal cognitive-behavioral therapy)
Study: 21375445
Drug: Hypnosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis and acceptance and commitment therapy
Study: 16330291
Drug: RSG/MET (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/MET (4 mg/2 g per day, escalated to 8 mg/2 g per day)
Study: 16330291
Drug: MET (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET (2.5 g/d, escalated to 3 g/d)
Study: 2737799
Drug: sustained-release capsule
Normalized name: Dilacor 240mg Sustained-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release capsule with breakfast
Study: 2737799
Drug: sustained-release capsule
Normalized name: Dilacor 240mg Sustained-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release capsule in fasting state
Study: 2737799
Drug: tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet form
Study: 24099237
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral mosapride
Study: 19783538
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg kg(‐1) bolus + 10 mg kg(‐1) h(‐1) continuous infusion (Mg 30 group)
Study: 19783538
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 45 mg kg(‐1) bolus + 15 mg kg(‐1) h(‐1) continuous infusion (Mg 45 group)
Study: 19783538
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (both Mg 30 and Mg 45 groups)
Study: 7781139
Drug: Hepsulfam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepsulfam at 800 mg/m2
Study: 7781139
Drug: Hepsulfam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepsulfam at 640 mg/m2
Study: 7781139
Drug: Hepsulfam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepsulfam at 480 mg/m2
Study: 7781139
Drug: Hepsulfam at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepsulfam at doses > or = 640 mg/m2
Study: 2332564
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (0.4 mg per day)
Study: 2332564
Drug: Oral budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral budesonide (1.4 mg per day)
Study: 7010511
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid therapy (20 mg of triamcinalone hexacetonide)
Study: 31371386
Drug: Weekly retraining
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly retraining (1-month group)
Study: 26121832
Drug: Composite acoustic
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite acoustic therapy (personalized) for the first 30 days, followed by music therapy for the next 31-90 days.
Study: 26121832
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sound therapy).
Study: 21457214
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0·05% ointment (n = 30)
Study: 21457214
Drug: Tacrolimus 0·1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0·1% ointment (n = 31)
Study: 19587362
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aliskiren and irbesartan
Study: 7816516
Drug: Both enteral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both enteral and parenteral feeding
Study: 29196578
Drug: Quinidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (300 mg/d)
Study: 29196578
Drug: Quinidine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (900 mg/d and 600 mg/d)
Study: 26603881
Drug: Prebiotic (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (50% inulin and 50% fructo-oligosaccharide), 6 g twice daily from 1 week before to 3 weeks after RT
Study: 26603881
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g maltodextrin twice daily from 1 week before to 3 weeks after RT)
Study: 25464565
Drug: D‐methionine tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐methionine tablets
Study: 22540883
Drug: Exenatide +
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide + metformin
Study: 27918443
Drug: Olive Leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive Leaf Extract (OLE) 20 mL daily for 8 weeks
Study: 23962455
Drug: Abatacept (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (125 mg weekly)
Study: 23962455
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg bi-weekly)
Study: 22648709
Drug: Alginate-based preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate-based preload supplement (15 g fiber)
Study: 22648709
Drug: Placebo preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preload supplement
Study: 20697939
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice a day and 20 mg mosapride thrice a day for a total duration of 6 weeks.
Study: 15941145
Drug: Allicor (Allium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicor (Allium sativum preparation) for 12 months
Study: 10577446
Drug: Ecadotril 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecadotril 50 to 400 mg twice daily
Study: 1678221
Drug: Histamine (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (1, 3.3, 10, 33, and 100 micrograms/ml) injected intradermally
Study: 7055526
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia with thiopentone, fentanyl and nitrous oxide, infusion of isotonic saline solution 5ml min‐1 (Group I)